Tremelimumab Biosimilar, Human CTLA-4 mAb
Item Information
Catalog #
Size
Price
Description
Tremelimumab (formerly Ticilimumab) is a human IgG2-kappa monoclonal antibody specific for human CTLA-4, a checkpoint protein expressed by T cells. Binding of Tremelimumab to CTLA-4 prevents it from suppressing the T cell during antigen presentation, freeing up the antigen-presenting cell to bind to the costimulatory molecule CD28 on the T cell; as a result, the T cell is activated instead of suppressed. This Tremelimumab biosimilar has the same amino acid sequence as Tremelimumab.
Product Overview
Isotype
IgG2 kappa
Source
Produced in a mammalian stable cell line.
Formulation
0.2-uM filtered solution, pH 7.4, no stabilizers or preservatives
Purity
>95% by SDS-PAGE under reducing conditions and HPLC
Endotoxin
<1 EU/mg (LAL method)
Specificity/Sensitivity
Binds to human CTLA-4.
Storage
4°C if used within 1 month, -20°C otherwise
Shipping Information
Shipped with an ice pack.
Application
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and assays for studying the biological pathways affected by Tremelimumab.
For Research Use Only. Not for use in diagnostic procedures.